Siren L.L.C. Sells 35,000 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Siren L.L.C. lessened its holdings in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 7.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 465,000 shares of the company’s stock after selling 35,000 shares during the period. BeOne Medicines makes up about 3.8% of Siren L.L.C.’s portfolio, making the stock its 5th biggest holding. Siren L.L.C.’s holdings in BeOne Medicines were worth $138,091,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ONC. EFG International AG acquired a new position in BeOne Medicines during the 4th quarter valued at about $25,000. Daiwa Securities Group Inc. purchased a new stake in BeOne Medicines in the second quarter valued at about $35,000. Leonteq Securities AG acquired a new stake in BeOne Medicines in the fourth quarter worth about $35,000. CWM LLC boosted its holdings in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after acquiring an additional 39 shares in the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the fourth quarter worth about $61,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne announced plans to invest an additional $300 million to expand its Hopewell, New Jersey manufacturing campus, reinforcing its U.S. footprint and bringing total investment in the facility to more than $1 billion. The move suggests confidence in long-term demand and could support future supply for its cancer drug pipeline. BeOne Medicines To Invest $300M In New Jersey Manufacturing Expansion
• Positive Sentiment: JPMorgan raised its price target on BeOne to $425 from $415 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s upside potential. Benzinga report on JPMorgan price target increase
• Positive Sentiment: Additional reports highlighted BeOne’s U.S. expansion and large capital commitment, which may be viewed by investors as a strategic growth investment rather than a one-off expense. BeOne Medicines expands New Jersey campus with additional $300 million investment
• Neutral Sentiment: One headline noted that a BeOne founder sold $34.6 million in stock, but the report also said the founder still holds a large position, making the signal mixed rather than clearly negative. A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position
• Neutral Sentiment: Analyst consensus data cited a roughly $391 average price target, which supports a constructive outlook but does not represent a new catalyst on its own. BeOne Medicines Ltd. Receives $390.92 Consensus PT from Analysts

Analyst Upgrades and Downgrades

ONC has been the topic of several recent analyst reports. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $436.00 to $451.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. Leerink Partners upped their price target on shares of BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Finally, Guggenheim raised their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $394.00.

BeOne Medicines Stock Up 2.1%

BeOne Medicines stock opened at $326.77 on Friday. The business’s 50-day simple moving average is $290.79 and its two-hundred day simple moving average is $309.32. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The company has a market cap of $35.85 billion, a PE ratio of 73.10 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. Equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Insider Buying and Selling

In other news, insider Lai Wang sold 1,367 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $269.38, for a total value of $368,242.46. Following the sale, the insider directly owned 40 shares of the company’s stock, valued at $10,775.20. This represents a 97.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the stock in a transaction on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the sale, the chief executive officer owned 8,122 shares in the company, valued at $2,484,925.90. The trade was a 94.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 233,647 shares of company stock worth $70,335,553. 6.19% of the stock is owned by company insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.